ArticleSurgical case reports2026
Humoral Hypercalcemia of Malignancy Caused by Parathyroid Hormone-Related Protein-Secreting Medullary Thyroid Carcinoma: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor arising from the parafollicular C cells, accounting for approximately 1.5% of all thyroid cancers. Although calcitonin secreted by the MTC typically lowers calcium levels, serum calcium concentrations usually remain within the normal range due to compensatory parathyroid hormone (PTH) secretion. Hypercalcemia of malignancy is broadly categorized as humoral hypercalcemia of malignancy (HHM), mediated by parathyroid hormone-related protein (PTHrP), or local osteolytic hypercalcemia. We report a rare case of HHM caused by a PTHrP-secreting MTC. CASE PRESENTATION: A 60-year-old woman visited our hospital with weight loss, fatigue, and a large right-sided neck mass. Laboratory tests revealed marked hypercalcemia (16.5 mg/dL), hypophosphatemia, and renal dysfunction. The intact PTH level was within the normal range, whereas the PTHrP level was elevated to 5.7 pmol/L, consistent with HHM. Tumor marker analysis revealed marked increases in carcinoembryonic antigen and calcitonin levels. Imaging studies revealed a large mass in the right thyroid lobe without evidence of regional or distant metastasis. Fine-needle aspiration confirmed the diagnosis of MTC. Genetic testing was negative for rearranged during transfection mutations and multiple endocrine neoplasia 2A, supporting a sporadic form. Hypercalcemia was managed with intravenous hydration (saline solution, 2 L/day for 10 days), elcatonin (80 units/day for 9 days), and a single dose of zoledronic acid. The patient underwent a right thyroid lobectomy. Histopathological analysis confirmed MTC without extra-thyroidal extension or lymph node metastasis (Union for International Cancer Control pT3aN0M0 stageII). Postoperatively, the serum PTHrP levels decreased to normal, and the patient recovered without complications. At the 8-month follow-up, no evidence of recurrence was observed.
conclusionsHerein, we present a rare case of MTC that caused hypercalcemia via PTHrP production. Although HHM is uncommon in thyroid cancer, the condition can cause severe hypercalcemia requiring prompt diagnosis and treatment. HHM should be considered in patients with thyroid cancer with hypercalcemia, and PTHrP measurement may aid in the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.